经胸廓切开植入HeartMate 3左心室辅助装置的多中心单臂研究
HM3 SWIFT研究为前瞻性、多中心、单臂研究,2020年12月至2022年7月在23个北美中心纳入102例适合经胸廓切开技术植入HeartMate 3的患者,与倾向性评分匹配队列比较,6个月复合主要终点达到非劣效(绝对组间差异-1.2%,Farrington Manning单侧95%CI下限-9.3%,P<.0025),无事件生存率无差异(85.0% vs 86.2%;HR 1.01;95%CI 0.58-2.10),但经胸廓切开组住院时间更长(中位20 vs 17天;P=.03)。
要点
- 经胸廓切开植入HeartMate 3的6个月复合主要终点非劣效于标准正中开胸。
- 无事件生存率经胸廓切开组85.0% vs 匹配队列86.2%,无统计学差异。
- 经胸廓切开组住院时间更长(中位20 vs 17天;P=.03)。
核心结论
- 经胸廓切开植入HeartMate 3左心室辅助装置非劣效于标准全正中开胸植入。
- 本研究支持经胸廓切开植入作为HeartMate 3左心室辅助装置外科植入的附加标准。
研究设计与样本
- 前瞻性、多中心、单臂研究,2020年12月至2022年7月在23个北美中心纳入102例适合经胸廓切开技术(双侧胸廓切开或部分上段胸骨切开联合左胸廓切开)植入HeartMate 3的患者。
- 主要终点为6个月无致残性卒中(改良Rankin评分>3)、无因装置故障再次手术移除或更换、无中转正中开胸的复合终点(择期移植视为成功),非劣效界值-15%,把握度>90%,与来自HeartMate 3持续准入方案多中心磁悬浮技术研究的倾向性评分匹配队列(比例1:2)比较。
- 随访于2022年12月结束。
主要发现
- 主要终点达到非劣效(绝对组间差异-1.2%;Farrington Manning单侧95%CI下限-9.3%;P<.0025)。
- 无事件生存率经胸廓切开组85.0% vs 匹配队列86.2%(HR 1.01;95%CI 0.58-2.10),无差异。
- 经胸廓切开组住院时间更长(中位20 vs 17天;P=.03)。
- 两组在血制品使用、不良事件(包括右心衰竭)、功能状态和生活质量方面无差异。
关键数值与推荐
- 主要终点非劣效界值为-15%。
- 主要终点绝对组间差异-1.2%,Farrington Manning单侧95%CI下限-9.3%,P<.0025。
- 无事件生存率经胸廓切开组85.0% vs 匹配队列86.2%;HR 1.01;95%CI 0.58-2.10。
- 住院时间中位数经胸廓切开组20天 vs 匹配队列17天;P=.03。
临床怎么用
- 经胸廓切开植入可作为HeartMate 3左心室辅助装置外科植入的附加标准。
- 经胸廓切开植入与标准正中开胸相比,血制品使用、不良事件(包括右心衰竭)、功能状态和生活质量无差异,但住院时间更长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The HeartMate 3 (Abbott) left ventricular assist device provides substantial improvement in long-term morbidity and mortality in patients with advanced heart failure. The Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical Techniques Other Than Full Median Sternotomy study compares thoracotomy-based implantation clinical outcomes with standard median sternotomy. METHODS: We conducted a prospective, multicenter, single-arm study in patients eligible for HeartMate 3 implantation with thoracotomy-based surgical technique (bilateral thoracotomy or partial upper sternotomy with left thoracotomy). The composite primary end point was survival free of disabling stroke (modified Rankin score >3), or reoperation to remove or replace a malfunctioning device, or conversion to median sternotomy at 6-months postimplant (elective transplants were treated as a success). The primary end point (noninferiority, -15% margin) was assessed with >90% power compared with a propensity score-matched cohort (ratio 1:2) derived from the Multi-Center Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 continued access protocol. RESULTS: The study enrolled 102 patients between December 2020 and July 2022 in the thoracotomy-based arm at 23 North American centers. Follow-up concluded in December 2022. In the Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical Techniques Other Than Full Median Sternotomy study group, noninferiority criteria was met (absolute between-group difference, -1.2%; Farrington Manning lower 1-sided 95% CI, -9.3%; P < .0025) and event-free survival was not different (85.0% vs 86.2%; hazard ratio, 1.01; 95% CI, 0.58-2.10). Length of stay with thoracotomy-based implant was longer (median, 20 vs 17 days; P = .03). No differences were observed for blood product utilization, adverse events (including right heart failure), functional status, and quality of life between cohorts. CONCLUSIONS: Thoracotomy-based implantation of the HeartMate 3 left ventricular assist device is noninferior to implantation via standard full sternotomy. This study supports thoracotomy-based implantation as an additional standard for surgical implantation of the HeartMate 3 left ventricular assist device.
引用
- Gosev I, Pham DT, Um JY, et al. Ventricular assist device using a thoracotomy-based implant technique: Multi-Center Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical Techniques Other Than Full Median Sternotomy (HM3 SWIFT). J Thorac Cardiovasc Surg. 2024. PMID: 38367698. doi:10.1016/j.jtcvs.2024.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。